Living with uncertainty: antidepressants and pregnancy

Summary There have been a large number of studies in recent years reporting on the reproductive safety of antidepressant medication. Some studies, but not all, have reported an association of antidepressant exposure in pregnancy and the subsequent development of autism spectrum disorders. It remains difficult to know whether the modest increase in risk is due to the medication, to the mood disorder itself, or to other confounding factors. For any individual woman the decision to commence or continue antidepressant medication in pregnancy must be made after a full consideration of the potential risks and benefits of all options, including non-pharmacological treatments. In making these difficult decisions it is important to recognise that episodes of severe psychiatric illness may have very serious negative consequences for the woman, her baby and her family, and these must be weighed against what is known about the risks of taking medication.

[1]  A. Hofman,et al.  Prenatal exposure to selective serotonin reuptake inhibitors and social responsiveness symptoms of autism: population-based study of young children , 2014, British Journal of Psychiatry.

[2]  M. Melbye,et al.  Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. , 2013, The New England journal of medicine.

[3]  D. Schendel,et al.  Antidepressant exposure in pregnancy and risk of autism spectrum disorders , 2013, Clinical epidemiology.

[4]  C. Torp-Pedersen,et al.  Prevalence of Antidepressant Use during Pregnancy in Denmark, a Nation-Wide Cohort Study , 2013, PloS one.

[5]  Brian K. Lee,et al.  Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study , 2013, BMJ : British Medical Journal.

[6]  J. Rehm,et al.  Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. , 2013, The Journal of clinical psychiatry.

[7]  A. Edwards,et al.  Communicating risk , 2012, BMJ : British Medical Journal.

[8]  L. Croen,et al.  Antidepressant use during pregnancy and childhood autism spectrum disorders. , 2011, Archives of general psychiatry.

[9]  I. Petersen,et al.  Pregnancy as a major determinant for discontinuation of antidepressants: an analysis of data from The Health Improvement Network. , 2011, The Journal of clinical psychiatry.

[10]  M. Gissler,et al.  Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries , 2011, BMJ : British Medical Journal.

[11]  S. Ephross,et al.  Paroxetine in the first trimester and the prevalence of congenital malformations , 2007, Pharmacoepidemiology and drug safety.

[12]  B. Källén,et al.  Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. , 2007, Birth defects research. Part A, Clinical and molecular teratology.